Gilead's Price Battle with Express Scripts | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Breaking News: Viekira Pak Approved for Hep C

Back to News Homepage
Next

Which Pharmacy Will Exclusively List Gilead on its Hep C Formularies?

Gilead’s Price Battle with Express Scripts

The Editors at Hepatitis Central
December 24, 2014

Print this page

Why has Gilead resisted lowering its Hepatitis C drug prices with Express Scripts’ National Preferred Formulary, a list of approved and covered drugs for millions of Americans?

Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival

By Caroline Humer

(Reuters) – The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc’s newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc’s treatments after trying for nearly a year to win a deeper discount.

Express Scripts’ move reignited investor concerns that pharmaceutical companies will have to bow to pricing pressure from U.S. insurers and lawmakers over novel medications whose cost can reach hundreds of thousands of dollars for some diseases.

Continue reading this entire article:
https://news.yahoo.com/express-scripts-cover-abbvie-hepatitis-c-drug-drops-050323412–finance.html

8 Comments
Share
Share
Previous

Breaking News: Viekira Pak Approved for Hep C

Back to News Homepage
Next

Which Pharmacy Will Exclusively List Gilead on its Hep C Formularies?

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.